DOCSLIB.ORG

Front Matter

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY VOLUME 27 * JUNE 1985 * NUMBER 6 Leon H. Schmidt, Edlitor in Chief (1985) Robert C. Moellering, Jr., Etlitor (1987) Unlivevr.sity of Alabana in Bi-inif'/igllam NVw' Etiglant Dco(t0iesS ILHoJspital Birmiiinghattn Bostoti, Ma.so(lahsetts Herbert L. Ennis, Editor (1987) Christine C. Sanders, Editor, (1989) Roche Institiute of AMole(ula(l Biology Creightoni Universitv Sc(0hoolfoV'(lidcil( Nmutlev, Newi, Jer-seyv Omaha, Nebraska Robert L. Hamill, Editor (1985) Peter G. Welling, Eklitor (1988) Eli Lil//, & Colfnpany l(c. Warl Clr-La/Ub/t Co. Indiaina(lpolis, lntdianlal A tin Arbor, Michigall George A. Jacoby, Jr., Elitor (1985) John A. Washington II, Editor (1986) Massachusetts Generatil Hospital Mayo Clinic Boston Rochester. NIilhlC 'vota EDITORIAL BOARD Norris Allen (1986) Arthur English (1986) Joan Lusk (1986) Nlerle Sande (198>() Vincent T. Andriole (1987) Robert J. Fass (1985) R. Luthy (1986) NV. Eugene Sanders, Jr. (1987) Bascom F. Anthony (1985) Stuart Feldman (1985) Francis L. Macrina (1985) WV. NMichael Scheld (1986) George R. Aronoff (1986) Sydney Finegold (1985) Gerald L. Mandell (1986) Jerome J. Schentag (1985) Robert Austrian (1986) Robert J. Fitzgerald (1986) Garv R. Matzke (1986) Raymond F. Schinazi (1986) Richard H. Baltz (1987) Martin Forbes (1986) George H. McCracken (1987) Fritz D. Schoenknecht (1986) Rashmi H. Barbhaiya (1986) John N. Galgiani (1987) Antone A. Medeiros (1987) F. C. Sciavolino (1985) Arthur L. Barry (1986) Dale N. Gerding (1985) Gerald Medoff (1986) VW'illiam NI. Shannon (1986) John G. Bartlett (1987) Anthony J. Glazko (1987) NMichael Miller (1987) Charles Shipman, Jr. (1985) Michael Barza (1985) Irving H. Goldberg (1985) Barbara Minshew (1985) Robert NV. Sidwell (1987) William M. Bennett (1987) Jack Gwaltnev (1986) Thomas P. Moyer (1986) P. Frederick Sparling (1987) Richard F. Bergstrom (1985) Scott NI. Hammer (1986) Barbara E. Murrav (1987) Harold Standiford (1985) Karen K. Biron (1987) W. Lee Hand (1986) John D. Nelson (1986) I)avid A. Stevens (1986) Gerald P. Bodey (1986) H. Hunter Handsfield (1986) Harold C. Neu (1986) Stephen E. Straus (1987) Arthur E. Brown (1987) Joseph Hawkins, Jr. (1985) Lawrence A. Pachla (1987) R. Sutherland (1985) Lawrence E. Bryan (1985) Frederick G. Hayden (1987) Joseph S. Pagano (1987) Morton N. Swartz (1985) Ward Bullock (1987) Nlichael Higgins (1986) James 'T. Park (1985) Richard B. Sykes (1985) Tsun Chang (1986) David C. Hooper (1987) James E. Pennington (1986) Francis P. Tally (1987) Anthony Chow (1985) Richard Hornick (1986) T. J. Perun (1986) Alexander Tomasz (1985) C. Glenn Cobbs (1986) George Gee Jackson (1986) Lance R. Peterson (198X5) Ralph Tompsett (1985) Paul S. Cohen (1986) James H. Jorgensen (1987) Michael Rein (1986) Francis L. S. Tse (1986) William A. Craig (1987) William J. Jusko (1986) W. H. G. Richards (1986) Richard J1. Wallace, Jr. (1987) Naomi Datta (1987) A. W. Karchmer (1985) Richard Roberts (1985) Michael W'aring (1987) Lawrence E. Day (1986) Donald Kaye (1985) Ian M. Rollo (1985) Bernard XN'eisblum (1985) William E. Dismukes (1987) George S. Kobayashi (1985) Allan Ronald (1987) Richard NI. Welch (1986) R. Gordon Douglas, Jr. (1986) Donald J. Krogstad (1986) Richard Root (1986) Richard Wise (1986) John C. Drach (1987) Felix Leitner (1986) John P. Rosazza (1986) John S. Wolfson (1987) George L. Drusano (1987) Stephen A. Lerner (1986) Jon E. Rosenblatt (1985) Lowell Young (1985) Theodore Eickhoff (1985) Stuart B. Levv (1986) Robert H. Rubin (1987) Pauline K. WV. Yu (1985) Gertrude B. Elion (1987) Helen R. Whiteley, Chairman,ti. Publication.s Board Walter G. Peter III, Director of Publications Linda M. Illig, Managing Editor, Jourtnals Deborah J. Shuman, Production Edit(or Antimicrobial Agents antid Chemotherapy (ISSN 0066-4804). an interdisciplinary publication of the American Societs for Microbiology. 1913 I St., NW, Washington, DC 20006, is devoted to the dissemination of knowledge relating to all aspects of antimicrobial. antiparasitic. and anticancer agents and chemotherapy. Instructions to authors are published in the JamnuIary issue each year; reprints clre available fr-om the editors and the Publications Departmient. Antimicrobial A,cnts anditl CheMotherIaP is published monthly. and the twelve number-s are dividedc into two volumes per year. The nonmember suLbscription price is $157 per year: single copies are $21. The member subscription price is $31 (foreign, $41 [surface rate]) per year; single copies are $7. Correspondence relating to subsCIiptions, reprints, defective copies. illlability of back issues, lost or late proofs. disposition of submittedimanuscripts, and general editorial matters shouLld be directed to the ASM Publications Department. 1913 I St.. NW, Washington. DC 20006 (phone: 202 833-9680). Claims for missing issues from residents of the United States. Canada. and Mexico must be submitted within 3 months after publication of the issues; residents of all other countries must submit claiims within 6 months of publication of the issues. Claims for issues missing becaLuse of failure to report an address change or for issuLes "missing from files" will not be allowed. Second-class postage paid at Washington. DC 20006. and at additional mailing offices. POSTMASTER: Send address changes to Antimicrobial Agentts antd( Chemnthorapv. ASM. 1913 1 St.. NW. Washington. D)C 20006. Made in the United States of America. Copyright L': 1985, American Society for Microbiology. E] )f VeK.ki,,-JXI, RI jt All Rights Reserved. The code at the top of the first page of an article in this journal indicates the copyright owner's consent that copies of the article mtlay be made for personal use or for personal use of specific clients. This consent is given on the condition, however, that the copier- pay the stated per-copy fee through the Copyright Clearance Ceniter, Inc.. 21 Congress St.. Salem, MI\A ((1970). for copying beyond that per-mitted by Sections 107 and 108 of the U.S. Copyright Law. This consent dloes not extend to other kinds of copying. sLuch as copying for- generll distributionl, for advertising or promotional purposes, for creating new collective works, or for- reslle. Author Index Alving, Carl R., 903 Gavan, Thomas L., 982 Kuhrt, M. F., 883 Raymond, Gilles, 928 Attfield, P. V., 985 George, W. Lance, 966 Reinhardt, John F., 966 Ayers, Leona W., 982 Gerlach, E. Hugh, 982 Lawrence, Adam G., 964 Rill, Wayne L., 903 Gilbert, David N., 897 Leathers, Timothy, 892 Ryan, D. Michael, 925 Beale, Angela S., 980 Giles, Penelope, 953 Lemieux, Michel, 928 Bennett, William M., 897 Giovenella, Albert J., 961 Lessard, Celine, 928 San Joaquin, Venusto H., 908 Bergeron, Michel G., 928 Gorbach, Sherwood L., 968 Lindqvist, Lennart, 943 Shalit, Itamar, 908 Berman, Jonathan D., 916 Grappel, Sarah F., 961 Lin, Jung-Chung, 971 Skold, Ola, 933 Boon, Ronald J., 980 Greenberg, Stephen B., 953 Luman, J. Ileice, 912 Smith, M. Carolyn, 971 Brander, Pirkko, 948 Sommers, Herbert M., 982 Brochu, Gilles, 928 Hadley, W. Keith, 958 Madigan, Sanford, 974 Steele, Lorraine C., 912 Brooks, Dandrea L., 912 Hanson, Brian D., 916 Marks, Melvin I., 908 Steen, Rolf, 933 Harris, Deborah, 953 Martin, R. Russell, 953 Stevenson, Roselynn M. W., 938 Canonico, Peter G., 903 Holland, Susan, 989 Mayor, Gilbert, 897 Suzuki, Yasuhiko, 921 Houang, Elizabeth T., 964 McColm, Andrew A., 925 Swartz, Glenn M., Jr., 903 Dale, Jeremy W., 989 Houghton, Donald C., 897 McKinlay, M. A., 883 Sweet, Richard L., 958 Dandu, Vijay R., 977 McLarty, Jerry W., 912 Sypherd, Paul S., 892 De Grandis, Stephanie A., 938 Jackson, Andre J., 977 Mdtras, Jacques, 928 Desaulniers, Denis, 928 Jacobus, Nilda V., 968 Mordenti, Joyce, 887 Despres, Jean-Paul, 928 Jokipii, Anssi M. M., 948 Tally, Francis P., 968 Diana, G. D., 883 Jokipii, Liisa, 948 Nagata, Akihisa, 921 Tuner, Kajsa, 943 Dias, M. Beatriz Souza, 968 Jones, J., 966 Nisbet, Louis J., 961 Didolkar, Mukund S., 977 Jones, Ronald N., 982 Nord, Carl Erik, 943 Waddell, David, 916 English, Jan, 897 Ohm-Smith, Marilyn J., 958 Wallace, Richard J., Jr., 912, 953 Kasbekar, Durgadas P., 974 Ono, Yasuko, 921 Welch, David F., 908 Fancher, M. J., 883 Katz, Eugene, 974 Otto, M. J., 883 Wilson, Rebecca W., 912 Fiore, Dario, 977 Kende, Meir, 903 Fowlston, S., 966 Kohlhepp, Sue, 897 Pagano, Joseph S., 971 Yamada, Takeshi, 921 Fox, M. P., 883 Kohnen, Paul W., 897 Pinney, R. J., 985 Yamanouchi, Takahisa, 921 AUTHOR INDEX VOLUME 27 Aalen, Odd, 107 Bowman, Bernard U., Jr., 399, Dale, Jeremy W., 989 Fliegelman, Robert M., 429 Adams, M., 275 404, 408 Dandu, Vijay R., 977 Fontana, Roberta, 828 Aiba, Shuichi, 367 Box, Quellin T., 181 D'Aquino, Miguel, 137 Forrest, A., 605 Alexander, W. James, 760 Brajtburg, Janina, 172 Datema, Roelf, 753 Fowlston, S., 966 Allan, J. Davis, 782 Brammer, Keith W., 832 David, Hugo L., 701 Fox, Jack J., 733 Alpert, Martin L., 422 Brander, Pirkko, 948 Debbia, Eugenio, 615 Fox, M. P., 883 Alvarez, Salvador, 646 Brandis, Henning, 836 De Grandis, Stephanie A., 938 Frank, Karl B., 445 Alving, Carl R., 903 Brater, D. C., 436 DeHertogh, Deborah A., 670 Freij, Bishara J., 431 Ambinder, Richard F., 217 Brier, Michael E., 812 Delaha, Edward C., 485 Friedhoff, Lawrence T., 263 Anderson, R., 257 Brier, Richard A., 812 Delatour, Frederique, 520 Friedman-Kien, Alvin E., 763 Anwar, Hosmin, 220 Brion, Nils, 520, 660 Del Bene, Victor E., 817 Fuchs, Peter C., 679 Aoki, Fred Y., 753 Brochu, Gilles, 928 DeLong, Donald C., 102 Fujii, Tadashi, 608, 612 Aoyama, M., 595 Brooks, Dandrea L., 912 de Lorenzo, Victor, 666 Fujiwara, Tatsushi, 65 Apicella, Michael A., 16 Brown, Michael R. W., 220 de Miguel, Constantino, 76 Arao, Nakako, 565 Brummer, Elmer, 363 De Mol, Patrick, 388 Galask, Rudi, 337 Araujo, Fausto G., 491 Bruns, Wolfgang, 632 Desaulniers, Denis, 928 Gallion, Corinne, 503 Arizpe, H. M., 184 Bryan, Elza R., 102 Desjardins-Giasson, Suzanne, Garaci, E., 625 Arnold, Keith, 192 Buck, R.
Recommended publications
  • Breeding Laboratories (Hino, Japan)

    Breeding Laboratories (Hino, Japan)

    VOL. XLII NO. 6 THE JOURNAL OF ANTIBIOTICS 989 STIMULATORY EFFECT OF CEFODIZIME ON MACROPHAGE- MEDIATED PHAGOCYTOSIS Kazunori Oishi, Keizo Matsumoto, Masashi Yamamoto, Toshihiro Morito and Toshiaki Yoshida Department of Internal Medicine, Institute of Tropical Medicine, Nagasaki University, 12-4 Sakamoto-machi, Nagasaki 852, Japan (Received for publication January 27, 1989) Weevaluated the ingestion of anti-sheep erythrocyte (anti-E) IgG- and IgM-coated sheep erythiocytes by murineperitoneal macrophagesexposed to cefodizime, a newsemisynthetic cephalosporin, and other antibiotics. Cefodizime enhanced the ingestion of anti-E IgG- coated erythrocytes by peritoneal macrophages from CD-I and BALB/cmice in a dose- dependent manner, but had no effect on uncoated or IgM-coated erythrocytes. Similar enhancement was observed only in the case of cefpimizole (AC-1370), among the other anti- biotics examined. These results suggest that the favorable in vivo activity of cefodizime and cefpimizole may result from their phagocytosis-enhancing as well as antimicrobial properties. The new semisynthetic cephalosporin, cefodizime, is characterized by a cephem ring which con- tains a ^w-methoxyimino-aminothiazolyl group at the 7-position and a thiazolylthio-methyl group at the 3-position. The latter substitution is thought to provide metabolic stability and a prolonged half-life in humanserum0. The efficacy of cefodizime in experimental murine infections is apparently superior to that predicted from in vitro activity2>3). Wepostulated that the enhanced in vivo activity of cefodizime may be due to drug-induced immunostimulation. This speculation was in part based upon the previous demonstration that a variety of agents, including lysophosphatidylcholine4) and fibronectin5), enhance receptor-dependent phagocytosis. Moreover, it was previously reported that cefpimizole (AC-1370), another semisynthetic cephalosporin, potentiated phagocyte function of macrophages and neutrophils6).
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
  • WO 2010/025328 Al

    WO 2010/025328 Al

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 4 March 2010 (04.03.2010) WO 2010/025328 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, PCT/US2009/055306 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 28 August 2009 (28.08.2009) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (26) Publication Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/092,497 28 August 2008 (28.08.2008) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): FOR¬ GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, EST LABORATORIES HOLDINGS LIMITED [IE/ ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, —]; 18 Parliament Street, Milner House, Hamilton, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, Bermuda HM12 (BM).
  • Computational Antibiotics Book

    Computational Antibiotics Book

    Andrew V DeLong, Jared C Harris, Brittany S Larcart, Chandler B Massey, Chelsie D Northcutt, Somuayiro N Nwokike, Oscar A Otieno, Harsh M Patel, Mehulkumar P Patel, Pratik Pravin Patel, Eugene I Rowell, Brandon M Rush, Marc-Edwin G Saint-Louis, Amy M Vardeman, Felicia N Woods, Giso Abadi, Thomas J. Manning Computational Antibiotics Valdosta State University is located in South Georgia. Computational Antibiotics Index • Computational Details and Website Access (p. 8) • Acknowledgements (p. 9) • Dedications (p. 11) • Antibiotic Historical Introduction (p. 13) Introduction to Antibiotic groups • Penicillin’s (p. 21) • Carbapenems (p. 22) • Oxazolidines (p. 23) • Rifamycin (p. 24) • Lincosamides (p. 25) • Quinolones (p. 26) • Polypeptides antibiotics (p. 27) • Glycopeptide Antibiotics (p. 28) • Sulfonamides (p. 29) • Lipoglycopeptides (p. 30) • First Generation Cephalosporins (p. 31) • Cephalosporin Third Generation (p. 32) • Fourth-Generation Cephalosporins (p. 33) • Fifth Generation Cephalosporin’s (p. 34) • Tetracycline antibiotics (p. 35) Computational Antibiotics Antibiotics Covered (in alphabetical order) Amikacin (p. 36) Cefempidone (p. 98) Ceftizoxime (p. 159) Amoxicillin (p. 38) Cefepime (p. 100) Ceftobiprole (p. 161) Ampicillin (p. 40) Cefetamet (p. 102) Ceftoxide (p. 163) Arsphenamine (p. 42) Cefetrizole (p. 104) Ceftriaxone (p. 165) Azithromycin (p.44) Cefivitril (p. 106) Cefuracetime (p. 167) Aziocillin (p. 46) Cefixime (p. 108) Cefuroxime (p. 169) Aztreonam (p.48) Cefmatilen ( p. 110) Cefuzonam (p. 171) Bacampicillin (p. 50) Cefmetazole (p. 112) Cefalexin (p. 173) Bacitracin (p. 52) Cefodizime (p. 114) Chloramphenicol (p.175) Balofloxacin (p. 54) Cefonicid (p. 116) Cilastatin (p. 177) Carbenicillin (p. 56) Cefoperazone (p. 118) Ciprofloxacin (p. 179) Cefacetrile (p. 58) Cefoselis (p. 120) Clarithromycin (p. 181) Cefaclor (p.
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule

    Pharmaceutical Appendix to the Harmonized Tariff Schedule

    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule

    Pharmaceutical Appendix to the Harmonized Tariff Schedule

    Harmonized Tariff Schedule of the United States (2020) Revision 8 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 8 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

    Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
  • Pharmaceutical Appendix to the Harmonized Tariff

    Pharmaceutical Appendix to the Harmonized Tariff

    Harmonized Tariff Schedule of the United States (2019) Revision 11 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2019) Revision 11 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
  • Directed Molecular Evolution of Fourth-Generation Cephalosporin Resistance in Wellington Moore Iowa State University

    Directed Molecular Evolution of Fourth-Generation Cephalosporin Resistance in Wellington Moore Iowa State University

    Iowa State University Capstones, Theses and Graduate Theses and Dissertations Dissertations 2011 Directed molecular evolution of fourth-generation cephalosporin resistance in Wellington Moore Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/etd Part of the Medical Sciences Commons Recommended Citation Moore, Wellington, "Directed molecular evolution of fourth-generation cephalosporin resistance in" (2011). Graduate Theses and Dissertations. 10107. https://lib.dr.iastate.edu/etd/10107 This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. Directed molecular evolution of fourth-generation cephalosporin resistance in Salmonella and Yersinia by Wellington Moore A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Biomedical Science (Pharmacology) Program of Study Committee: Steve Carlson, Major Professor Timothy Day Ronald Griffith Iowa State University Ames, Iowa 2011 ii TABLE OF CONTENTS LIST OF FIGURES………………………………………………………………………iii LIST OF TABLES………………………………………………………………………..iv ABSTRACT……………………………………………………………………………….v CHAPTER 1. INTRODUCTION…………………………………………………………1 Review of B-Lactam antimicrobials………………………………...………1
  • Extended Spectrum Beta-Lactamases

    Extended Spectrum Beta-Lactamases

    Extended spectrum beta-lactamases A. Beta-lactam antibiotics a. Structure b. Types c. Action d. Mechanism of resistances B. Beta-lactamases a. Classical beta-lactamases b. Extended spectrum beta-lactamases (ESBL) c. Non-TEM, non-SBV ESBL d. Inhibitor Resistant TEM (IRT) C. Definition, classification and properties of ESBL D. Epidemiology and risk factors E. Laboratory detection and identification of ESBLs a. Screening, phenotypic and genotypic methods b. Co-production of ESBL and AmpC beta-lactamases F. Beta-lactamase inhibitors G. Multiple drug resistance H. Treatment options against ESBL producers A. Beta-lactam antibiotics A β-lactam (beta-lactam) ring is a four-membered cyclic amide consisting of three carbon atoms and one nitrogen atom. It is named so, because the nitrogen atom is attached to the β-carbon relative to the carbonyl (C=O). Antibiotics possessing this structure are called beta-lactam antibiotics. Penams contain a β-lactam ring fused to a 5- membered ring, where one of the atoms in the ring is a sulfur and the ring is fully saturated. A carbapenam is a β-lactam compound that is a saturated carbapenem. They exist primarily as biosynthetic intermediates on the way to the carbapenem antibiotics. A clavam is a molecule similar to a penam, but with an oxygen atom substituted for the sulfur. Thus, they are also known as oxapenams. Carbapenems are very similar to the penams, but the sulfur atom of the unsaturated structure is replaced with a carbon atom. Penem is a type of unsaturated β-lactam, which is similar in structure to carbapenems but penems have a sulfur atom instead of carbon.
  • Antibiotic Classes

    Antibiotic Classes

    Penicillins Aminoglycosides Generic Brand Name Generic Brand Name Amoxicillin Amoxil, Polymox, Trimox, Wymox Amikacin Amikin Ampicillin Omnipen, Polycillin, Polycillin-N, Gentamicin Garamycin, G-Mycin, Jenamicin Principen, Totacillin, Unasyn Kanamycin Kantrex Bacampicillin Spectrobid Neomycin Mycifradin, Myciguent Carbenicillin Geocillin, Geopen Netilmicin Netromycin Cloxacillin Cloxapen Paromomycin Dicloxacillin Dynapen, Dycill, Pathocil Streptomycin Flucloxacillin Flopen, Floxapen, Staphcillin Tobramycin Nebcin Mezlocillin Mezlin Nafcillin Nafcil, Nallpen, Unipen Quinolones Oxacillin Bactocill, Prostaphlin Generic Brand Name Penicillin G Bicillin L-A, First Generation Crysticillin 300 A.S., Pentids, Flumequine Flubactin Permapen, Pfizerpen, Pfizerpen- Nalidixic acid NegGam, Wintomylon AS, Wycillin Oxolinic acid Uroxin Penicillin V Beepen-VK, Betapen-VK, Piromidic acid Panacid Ledercillin VK, V-Cillin K Pipemidic acid Dolcol Piperacillin Pipracil, Zosyn Rosoxacin Eradacil Pivampicillin Second Generation Pivmecillinam Ciprofloxacin Cipro, Cipro XR, Ciprobay, Ciproxin Ticarcillin Ticar Enoxacin Enroxil, Penetrex Lomefloxacin Maxaquin Monobactams Nadifloxacin Acuatim, Nadoxin, Nadixa Generic Brand Name Norfloxacin Lexinor, Noroxin, Quinabic, Aztreonam Azactam, Cayston Janacin Ofloxacin Floxin, Oxaldin, Tarivid Carbapenems Pefloxacin Peflacine Generic Brand Name Rufloxacin Uroflox Imipenem, Primaxin Third Generation Imipenem/cilastatin Balofloxacin Baloxin Doripenem Doribax Gatifloxacin Tequin, Zymar Meropenem Merrem Grepafloxacin Raxar Ertapenem
  • Antimicrobial Composition

    Antimicrobial Composition

    Europa,schesP_ MM M II M MM 1 1 M Ml MM M Ml J European Patent Office .ha no © Publication number: 0 384 41 OBI Office europeen, desJ brevets © EUROPEAN PATENT SPECIFICATION © Date of publication of patent specification: 17.05.95 © Int. CI.6: A61 K 31/545, A61 K 31/43, //(A61K31/545,31:43) © Application number: 90103266.4 @ Date of filing: 20.02.90 The file contains technical information submitted after the application was filed and not included in this specification © Antimicrobial composition. ® Priority: 21.02.89 JP 41286/89 9-1, Kamimutsuna 3-chome 14.04.89 JP 94460/89 Okazaki-shi, Aichi (JP) @ Date of publication of application: Inventor: Sanada, Mlnoru, c/o BANYU PHARM. 29.08.90 Bulletin 90/35 CO., LTD. OKAZAKI RES. LABORATORY, © Publication of the grant of the patent: 9-1, Kamimutsuna 3-chome 17.05.95 Bulletin 95/20 Okazaki-shi, Aichi (JP) © Designated Contracting States: Inventor: Nakagawa, Susumu, c/o BANYU CH DE FR GB IT LI NL PHARM. CO., LTD. OKAZAKI RES. LABORATORY, © References cited: 9-1, Kamimutsuna 3-chome EP-A- 0 248 361 Okazaki-shi, Aichi (JP) UNLISTED DRUGS, vol. 37, no. 2, February Inventor: Tanaka, Nobuo, c/o BANYU PHARM. 1985, Chatham, New Jersey, US; "Zienam CO., LTD. 250". 2-3, Nihonbashi Honcho 2-chome Chuo-ku, © Proprietor: BANYU PHARMACEUTICAL CO., Tokyo (JP) LTD. Inventor: Inoue, Matsuhisa 2-3, Nihonbashi Honcho 2-chome 3076-3, Oaza-Tokisawa 00 Chuo-ku, Tokyo (JP) Fujlmi-mura, Seta-gun, @ Inventor: Matsuda, Kouji, c/o BANYU PHARM. Gunma (JP) CO., LTD.